Crescita Therpeutc (TSE:CTX) has released an update.
Crescita Therapeutics Inc., a Canadian dermatology company, has revitalized its partnership with a major global skin care company by signing an amended supply agreement worth $US10 million over four years. This agreement, which begins in 2025, will see Crescita manufacturing key products and compensates for previously cancelled orders, while also involving a capital investment by Crescita to upgrade its facilities.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.
